A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix.

@article{DueasGonzlez2009API,
  title={A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix.},
  author={Alfonso Due{\~n}as-Gonz{\'a}lez and Juan Jos{\'e} Zarb{\'a} and Juan Carlos Alcedo and P Pattarunataporn and Semir Be{\vs}lija and Firuza Patel and Lu{\'i}s Casanova and Helen Barraclough and Mauro Orlando},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={CRA5507}
}
CRA5507 Background: Cervical cancer is the second-most common cancer among women worldwide, in both incidence and mortality. Current standard therapy for locally advanced disease consists of concurrent Cis and external-beam radiation (XRT). This multicenter, open-label, randomized, phase III trial aimed to improve outcomes, capitalizing on the synergistic activity of Gem, Cis, XRT, and the potential value of adjuvant therapy. METHODS Eligible patients (pts) with bulky stage IIB to IVA, 18-70… CONTINUE READING